Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia

Bone Marrow Transplantation
R Morariu-ZamfirE Gluckman

Abstract

In order to study the influence of bone marrow CD34(+) cell dose on the outcome of allogeneic bone marrow transplantation (BMT), we analysed the results of BMT from HLA-identical siblings donors in 50 patients with chronic myeloid leukaemia (CML). The median numbers of nucleated cells (NC) and CD34(+) cells infused were 2.18 x 10(8)/kg (0.05-4.14 x 10(8)/kg) and 3.12 x 10(6)/kg (0.35-8.52 x 10(6)/kg), respectively. All patients engrafted. In univariate analysis, there was no correlation between the number of CD34(+) cells infused and the time to neutrophil recovery (P = 0.17). The Kaplan-Meier estimate of grade II-IV acute graft-versus-host disease (GVHD) at day 100 was 53 +/- 14% and 2-year survival was 46 +/- 15%. A number of CD34(+) cells infused greater than the median was the main factor increasing survival (P = 0.0006) and decreasing 100 day transplant-related mortality (P = 0.009). Patient-, disease- and transplant-related characteristics were not statistically different among patients receiving more or less than the median number of CD34(+) cells. The rate of infectious deaths was significantly higher in patients receiving less than 3.12 x 10(6) CD34/kg (48% vs 16%, P = 0.01). In a multivariable analysis, two factors as...Continue Reading

References

Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Oct 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W BensingerC Weaver
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·H VaziriP M Lansdorp
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Z S PavleticA Kessinger
Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S SienaC Carlo-Stella

❮ Previous
Next ❯

Citations

Nov 28, 2001·British Journal of Haematology·M BornhäuserUNKNOWN Cooperative German Transplant Study Group
Jan 19, 2002·Seminars in Hematology·Norbert Schmitz, John Barrett
Jul 28, 2005·Blood·Steven Z PavleticUNKNOWN National Heart, Lung, and Blood Institute Unrelated Donor Marrow Transplantation Trial
Jul 23, 2013·Bone Marrow Transplantation·J PidalaS J Lee
Feb 3, 2009·British Journal of Haematology·David MichonneauJérôme Larghero
Apr 22, 2015·Bone Marrow Transplantation·M RembergerJ Mattsson
Feb 11, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mats RembergerJonas Mattsson
Feb 5, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Herbert PichlerGerhard Fritsch
Aug 9, 2005·Current Opinion in Immunology·Anne M Dickinson, Dominique Charron
Mar 14, 2003·Bone Marrow Transplantation·A Kessinger, J G Sharp
Aug 31, 2018·Pediatric Transplantation·Vanessa FabrizioMichelle Hudspeth
May 16, 2003·Bone Marrow Transplantation·S Heimfeld

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.